Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

First site of relapse can predict different clinical courses in recurrent stage IIIA non-small cell lung cancer after definitive chemoradiotherapy

Date

08 Oct 2016

Session

Poster Display

Presenters

Keiko Goto

Citation

Annals of Oncology (2016) 27 (6): 411-415. 10.1093/annonc/mdw382

Authors

K. Goto1, H. Horinouchi1, Y. Goto1, S. Kanda1, Y. Fujiwara2, H. Nokihara3, N. Yamamoto1, Y. Ohe4

Author affiliations

  • 1 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Department Of Thoracic Oncology, National Cancer Center Hospital, Tokyo/JP
  • 3 National Cancer, Center Hospital, 104-0045 - Tokyo/JP
  • 4 Department Of Thoracic Oncology, National Cancer Center Hospital, 1040045 - Tokyo/JP
More

Resources

Background

The standard treatment for stage IIIA non-small cell lung cancer (NSCLC) is definitive chemoradiotherapy (dCRT). However, approximately 80% of patients experience relapse, resulting in a poor prognosis. The aim of this study was to evaluate the relapse patterns of patients with stage IIIA NSCLC after dCRT and their clinical courses.

Methods

A retrospective review of patients treated for stage IIIA NSCLC at the National Cancer Center between 2002 and 2011 was performed. Data on patients characteristics, the first relapse site after dCRT (inside or outside of the radiotherapy field, presence or absence of brain metastasis), salvage treatment, and the disease progression site after salvage treatment were collected. The post-progression overall survival (PPOS) was evaluated using the Kaplan-Meier method.

Results

Among the 152 patients who were treated with dCRT, 115 (76%) relapsed and were included in this analysis. Of these, infield recurrence (IR) and brain metastasis (BM) as a first relapse were observed in 30 (26%) and 14 (12%) patients, respectively. The other 71 patients (62%) experienced mixed recurrences (MR) including infield and distant metastases. Salvage treatments including radiotherapy, chemotherapy, and surgery were performed in 83 (72%) patients. In patients with IR, 2 patients (7%) underwent surgery, and the others were treated using chemotherapy. The median PPOS (mPPOS) and the 3-year PPOS (3yPPOS) rate in patients with IR were 16.8 months and 0%, respectively. All the patients with BM underwent local radiotherapy. The mPPOS and the 3yPPOS rate in patients with BM were 25.3 months and 39.3%, respectively. After salvage treatment, 17 (56%) of the 30 patients with IR experienced infield disease progression, and 10 (71%) of the 14 patients with BM developed CNS progression. In patients with MR, the mPPOS and 3yPPOS rate were 10.9 months and 17.2%, respectively.

Conclusions

Patients with IR tended to have a poorer prognosis than those with other patterns of relapse because of persistent local disease progression, while patients with BM experienced a better survival outcome. The development of an effective salvage therapy taking the recurrence pattern into account is mandatory.

Clinical trial identification

The study protocol was approved by the institutional review boards of the

National Cancer Center Hospital (number: 2015-355)

Legal entity responsible for the study

National Cancer Center

Funding

N/A

Disclosure

H. Horinouchi: Corporate-sponsored research: Taiho, Merck Serono, MSD, Astellas, Novartis. H. Nokihara: Honoraria: Boehringer Ingelheim, Taiho, AstraZeneca, Ono, Sanofi, Lilly Research Funding: Merck, Pfizer, Taiho, Eisai, Chugai, Lilly, Novartis, Daiichi Sankyo, GlaxoSmithKline, Yakult, Quintiles, Astellas, AstraZeneca, Boehringer Ingelheim, Ono. N. Yamamoto: Research funds (as institutions): Quintiles, Astellas, Chugai, Esai, Taiho, BMS, Pfizer, Novartis, Daiichi-Sankyo, Boehringer Ingelheim, Kyowa-Hakko Kirin. Honoraria: AstraZeneca, Pfizer, Lilly, Chugai. Y. Ohe: Reserch: AstraZeneca, Chugai, Lilly, Ono, BMS, Kyorin, Dainippon-Sumitomo, Pfizer, Taiho, Novaltis, Merc honoraria: AstraZeneca, Chugai, Lilly, Daiichi-Snkyo, Nippopnkayaku, Boehringer Ingelheim, Beyer, MSD, Taiho, Clovis, Sanofi. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings